Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination With Cetuximab, IMC-A12 or Both in Patients With Advanced Non-Small Cell Lung Cancer Who Will Not Receive Bevacizumab-Based Therapy.

Trial Profile

Three-Arm Randomized Phase II Study of Carboplatin and Paclitaxel in Combination With Cetuximab, IMC-A12 or Both in Patients With Advanced Non-Small Cell Lung Cancer Who Will Not Receive Bevacizumab-Based Therapy.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Sep 2014

At a glance

  • Drugs Cetuximab (Primary) ; Cixutumumab (Primary) ; Carboplatin; Paclitaxel
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 04 Sep 2013 Planned end date changed from 1 Jan 2011 to 1 Oct 2013 as reported by ClinicalTrials.gov.
    • 04 Sep 2013 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 18 Mar 2013 Status changed from suspended to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top